MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials.
MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types.
MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.
A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials.
MAIA’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types.
MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.
Location: United States, Illinois, Chicago
Employees: 11-50
Total raised: $8M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Checkmate ... | checkmatec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 19.05.2021 | - | $8M | - |
Mentions in press and media 3
| Date | Title | Description |
| 14.10.2021 | MAIA Biotechnology, Inc. : Announces $6.2 Million Financing to Advance Targeted Immuno-Oncology Studies | MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that it has raised an additional $6.2 million in an equity offering at $8/share. T... |
| 19.05.2021 | MAIA Biotechnology, Inc. : Raises $8.0 Million Financing to Advance Pipeline of Targeted Immuno-Oncology Studies | MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing first-in-class oncology drugs, today announced that it has raised $8.0 million financing in a convertible note offering led by new investor Checkmat... |
| 19.05.2021 | Maia Biotechnology Raises $8.0M in Funding | Maia Biotechnology, Inc., a Chicago IL-based immune-oncology company, raised $8.0m in funding. The round was led by Checkmate Capital Group, BRK Financial Group, and MDL Investments. The company intends to use the funds to advance its targe... |